HER2 Expression in Peritoneal Dissemination of High-Grade Serous Ovarian Carcinoma: A Comparative Study of Immunohistochemical Reactivity Using Four HER2 Antibodies.

J Clin Med · 2022 · PMC9741327 · PMID 36498537

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Log-rank testing for the pertuzumab efficacy showed a trend toward improved survival in patients with pHER2-positive tumors compared with patients with pHER2-negative tumors.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.